DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Zembrace Symtouch is a drug marketed by Upsher Smith Labs and is included in one NDA. There is one patent protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in ZEMBRACE SYMTOUCH is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
A generic version of ZEMBRACE SYMTOUCH was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Upsher Smith Labs||ZEMBRACE SYMTOUCH||sumatriptan succinate||SOLUTION;SUBCUTANEOUS||208223-001||Jan 28, 2016||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2017023361||Start Trial|
|European Patent Office||3331524||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|